Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 61, 2001 - Issue 6
Submit an article Journal homepage
45
Views
25
CrossRef citations to date
0
Altmetric
Research Article

Serum tumour markers CA 15-3, TPA, TPS, hCG β and TATI in the monitoring of chemotherapy response in metastatic breast cancer

J. Sjöström, Departments of Oncology,
,
H Alfthan Obstetrics and Gynaecology
,
H Joensuu Departments of Oncology,
,
U.H Stenman Obstetrics and Gynaecology
,
J Lundin Institute, Helsinki University Hospital, Finland;
&
C Blomqvist Department of Oncology,UppsalaUniversity Hospital,Uppsala, Sweden
Pages 431-441 | Published online: 08 Jul 2009

  • Anon. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1998; 16: 793-5.
  • Hilkens J, Buijs F, Hilgers J, Hageman P, Calafat J, Sonnenberg A, van der VaIk M. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984; 34: 197-206.
  • Peterson JA, Ceriani RL. Breast mucin and associated antigens in diagnosis and therapy. Adv Exp Med Biol 1994; 353: 1-8.
  • Sundström BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers 1994; 9: 102-8.
  • Björklund B, Björklund V. The proliferation marker concept with TPS as a model. A preliminary report. J Nucl Med Allied Sci 1990.
  • Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 1995; 76: 1467-75.
  • Agnantis NJ, Patra F, Khaldi L, Filis S. Immunohistochemical expression of subunit beta HCG in breast cancer. Eur J Gynaecol Oncol 1992; 13:461-6.
  • Stenman UH, Koivunen E, Itkonen O, Turpeinen U, Halila H, Huhtala ML. Tumour-associated trypsin inhibitor, TATI. Clinical use and biological function. Ann Chir Gynaecol 1989; 78: 77-82.
  • Koivunen E, Huhtala ML, Stenman UH. Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 1989; 264: 14095-9.
  • Alfthan H, Haglund C, Roberts P, Stenman U-H. Elevation of free ß-subunit of human choriogonadotropin and core ß fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res 1992; 52: 4628-33.
  • Venesmaa P, Stenman UH, Forss M, Leminen A, Lehtovirta P, Vartiainen J, Paavonen J. Preoperative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in stage III epithelial ovarian cancer. Br J Obstet Gynaecol 1998; 105: 508-11.
  • Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J. Docetaxel compared with sequential methotrexate and 5-fuorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-201.
  • Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
  • Alfthan H, Schröder J, Fraser R, Koskimies A, Halila H, Stenman U. Choriogonadotropin and its beta subunit separated by hydrophobicinteraction chromatography and quantified in serum during pregnancy by time-resolved immunofluorometric assays. Clin Chem 1988; 34: 1758-62.
  • Alfthan H, Haglund C, Dabek J, Stenman U. Concentrations of human Choriogonadotropin, its beta-subunit, and the core fragment of the betasubunit in serum and urine of men and nonpregnant women. Endocrinology 1992; 131: 1832-40.
  • Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283-98.
  • Willsher PC, Beaver J, Blarney RW, Robertson JF: Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA. Anticancer Res 1995; 15: 1609-11.
  • Blijlevens NM, Oosterhuis WP, Oosten HR, Mulder NH. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Anticancer Res 1995;15:2711-6.
  • Van Dalen A, van der Linde DL, Heering KJ, Blusse van Oudalblas A. How can treatment response be measured in breast cancer patients? Anticancer Res 1993; 13: 1901-4.
  • Van Dalen A, Heering K, Barak V, Peretz T, Cremaschi A, Geroni P, Gion M, Sarcchini S, Molin R, Namer M, Stieber P, Sturgeon C, Leonard R, Einarsson R. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes. The Breast 1996; 5: 82-8.
  • Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury JR, Grönberg H, Kumpulainen E, Blarney RW. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer 1999; 35: 47-53.
  • Sonoo H, Kurebayashi J. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 1996; 26: 250-7.
  • Pronk LC, Stoter G, van Putten WLJ, de Wit R. The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer. J Cancer Res Clin Oncol 1997; 123: 128-32.
  • Van Dalen A, Barak V, Cremaschi A, Gion M, Molina R, Namer M, Stieber P, Sturgeon C, Einarsson R. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int J Biol Markers 1998; 13: 10-5.
  • Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65: 193-9.
  • Schuurman JJ, Bong SB, Einarsson R. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 1996; 16: 2169-72.
  • Tyshler LB, Longton GM, Ellis GK, Livingston RB. False positive tumor markers: elevation in patients with breast cancer on FACtype chemotherapy and correlation with the development of hand-foot syndrome. Int J Biol Markers 1996; 11: 203-6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.